iSign Solutions (ISGN) 10-Q 15 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 15, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	iSign Solutions Inc.
Entity Central Index Key	0000727634
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-19301
Entity Interactive Data Current	Yes
Entity Incorporation state Country Code	DE
Entity Common Stock, Shares Outstanding		5,761,980

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 88	$ 25
Accounts receivable, net of allowance of $0 at March 31, 2020 and December 31, 2019, respectively	39	61
Prepaid expenses and other current assets	23	22
Total current assets	150	108
Property and equipment, net	7	8
Other assets	5	5
Total assets	162	121
Current liabilities:
Accounts payable	1,230	1,196
Short-term debt, net	2,396	2,246
Accrued compensation	85	71
Other accrued liabilities	883	814
Deferred revenue	453	346
Total current liabilities	5,047	4,673
Deferred revenue long-term		70
Other long-term liabilities	723	669
Total liabilities	5,770	5,412
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $0.01 par value; 2,000,000 shares authorized; 5,760 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	58	58
Treasury shares, 5 at March 31, 2020 and December 31, 2019, respectively	(325)	(325)
Additional paid in capital	129,673	129,651
Accumulated deficit	(135,014)	(134,675)
Total stockholders' deficit	(5,608)	(5,291)
Total liabilities and stockholders' deficit	$ 162	$ 121

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance	$ 0	$ 0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000	2,000
Common stock, shares issued	576	576
Common stock, shares outstanding	576	576
Treasury shares	5	5

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Product	$ 31	$ 41
Maintenance	159	158
Total revenue	190	199
Cost of sales:
Product	2	2
Maintenance	9	16
Research and development	176	171
Sales and marketing	27	26
General and administrative	228	204
Total operating costs and expenses	442	419
Loss from operations	(252)	(220)
Other income (expense) net	1
Warrant expense	(18)
Interest expense:
Related party	(24)	(14)
Other	(45)	(47)
Amortization of debt discount:
Related party		(3)
Other		(7)
Loss before income tax expense	(338)	(291)
Income tax expense	(1)
Net loss	$ (339)	$ (291)
Basic and diluted net loss per common share	$ (0.06)	$ (0.05)
Weighted average common shares outstanding, basic and diluted	5,762	5,762

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 58	$ (325)	$ 129,251	$ (133,589)	$ (4,605)
Balance, shares at Dec. 31, 2018	5,760	5
Stock-based compensation			59		59
Net loss				(291)	(291)
Balance at Mar. 31, 2019	$ 58	$ (325)	129,310	(133,880)	(4,837)
Balance, shares at Mar. 31, 2019	5,760	5
Balance at Dec. 31, 2019	$ 58	$ (325)	129,651	(134,675)	(5,291)
Balance, shares at Dec. 31, 2019	5,760	5
Stock-based compensation			22		22
Net loss				(339)	(339)
Balance at Mar. 31, 2020	$ 58	$ (325)	$ 129,673	$ (135,014)	$ (5,608)
Balance, shares at Mar. 31, 2020	5,760	5

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (339)	$ (291)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1	1
Amortization of debt discount		10
Amortization of warrants	19
Stock-based compensation	22	59
Changes in operating assets and liabilities:
Accounts receivable, net	22	41
Prepaid expenses and other assets	(1)	(13)
Accounts payable	34	(14)
Accrued compensation	14	(3)
Other accrued and long-term liabilities	104	112
Deferred revenue	37	45
Net cash used in operating activities	(87)	(53)
Cash flows from investing activities:
Acquisition of property and equipment		(2)
Net cash used in investing activities		(2)
Cash flows from financing activities:
Proceeds from the issuance of short-term debt	150
Net cash provided by financing activities	150
Net increase in cash and cash equivalents	63	(55)
Cash and cash equivalents at beginning of period	25	335
Cash and cash equivalents at end of period	88	280
Supplementary disclosure of cash flow information
Interest paid	4	1
Income taxes paid	$ 1

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	1. Nature of Business and Summary of Significant Accounting Policies Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign's solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign's platform can be deployed both on premise and as a cloud-based ("SaaS") service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company's products include SignatureOne™ Ceremony™ Server, the iSign™ suite of products and services, including iSign™ Enterprise and iSign™ Console™, and Sign-it™ programs. In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread to a number of other countries, including the U.S. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, several states in the U.S., including California, where the Company is headquartered, have declared a state of emergency. The COVID-19 outbreak is disrupting supply chains and affecting production and sales across a wide range of industries. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our customers, employees and vendors all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact our financial condition or results of operations is uncertain. Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2019. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2020 the Company's accumulated deficit was $135,014. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2020, the Company's cash balance was $88. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Update No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interaction between Topic 321, Topic 323 and Topic 815. The amended guidance in this update was issued to clarify the interaction of the accounting for equity securities under Topic 321, Investments—Equity Securities; investments accounted for under the equity method of accounting in Topic 323, Investments—Equity Method and Joint Ventures; and the accounting for certain forward contracts and purchased options accounted for under Topic 815, Derivatives and Hedging. The amendments are effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company will evaluate ASU 2020-01. The Company believes the adoption of ASU 2020-01 will have no impact on the Company's financial statements. Accounting Standards Update No. 2020-03, Codification Improvements to Financial Instruments. The Board decided to issue a separate update to improve various financial instruments Topics in the Codification to increase stakeholder awareness of the amendments and to clarify and improve the understandability of the guidance of Topics. The amendments are effective immediately. The Company believes the adoption of ASU 2020-03 will have no impact on the Company's financial statements.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2020
Risks and Uncertainties [Abstract]
Concentrations	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue 2020 2019 2020 2019 Customer #1 - - 12 % 12 % Customer #2 85 % 83 % 18 % 17 % Customer #3 - - 18 % 18 % Customer #4 - - 26 % 20 % Customer #5 13 % - - - Total concentration 98 % 83 % 74 % 67 %

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2020
Net Loss Per Share [Abstract]
Net Loss Per Share	3. Net Loss Per Share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted net income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of diluted earnings per share as the inclusion of shares from the assumed exercise of such options and warrants would be anti-dilutive: For the Three Months Ended March 31, 2020 March 31, 2019 Stock options 1,067 1,077 Warrants 2,536 2,813

Debt

Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	4. Debt Advances: In January and March 2020, the Company received, from affiliates, advances aggregating $75 in cash against certain accounts receivable of the Company. Upon collection of an invoice, the Company agreed to repay the advance to the lenders on a pro rata basis together with a 5% advance fee. On March 25, 2020, the affiliates converted their advances into unsecured notes. The Company paid the advance fees of $4 in cash, and recorded them as interest expense in the quarter ended March 31, 2020. Notes payable: On March 25, 2020, the Company issued an aggregate of $150 in unsecured notes to affiliates and other investors. The Company received $75 in cash and $75 in exchange for the advances discussed above. The notes bear interest at the rate of 10% per annum and are due December 31, 2020. During the three months ended March 31, 2020, the Company accrued $69 of interest expense, $60 associated with the outstanding secured and unsecured convertible promissory notes, of which $24 was to related parties and $36 was to other investors. For the three months ended March 31, 2019, the Company accrued $61 of interest expense, $53 associated with its outstanding notes, of which $13 was to related parties and $40 was to other investors. The Company recorded $0 and $10 in debt discount amortization for the three months ended March 31, 2020 and 2019, respectively.

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders’ Equity (Deficit)	5. Stockholders' Equity (Deficit) Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended March 31, 2020 and 2019 was approximately 6.43% and 5.95%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. No options were granted during the three months ended March 31, 2020. The Company granted stock options to purchase 40,000 shares of common stock during the three months ended March 31, 2019. There were no stock options exercised during the three months ended March 31, 2020 and 2019, respectively. The fair value calculations for the stock options granted are based on the following assumptions: Three Months Ended Risk free interest rate 2.30 % Expected life (years) 6.1 Expected volatility 191.65 % Expected dividend yield None The following table summarizes the allocation of stock-based compensation expense for the three months ended March 31: 2020 2019 Research and development $ 3 $ 10 Sales and marketing - ─ General and administrative 16 40 Director 3 9 Total stock-based compensation $ 22 $ 59 A summary of option activity under the Company's plans for the three months ended March 31, 2020 and 2019 is as follows: 2020 2019 Options Shares Weighted Average Exercise Price per share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price per share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1 1,077 $ 1.59 - $ - 1,037 $ 1.65 - - Granted - $ - - - 40 $ 0.50 - - Canceled (10 ) $ 56.10 Outstanding at March 31 1,067 $ 1.07 4.76 $ - 1,077 $ 1.61 5.72 - Vested and expected to vest at March 31 1,062 $ 1.59 4.92 $ - 1,077 $ 1.61 5.72 $ - Exercisable at March 31 736 $ 1.25 4.60 $ - 402 $ 3.24 5.28 $ - The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.01 - $0.50 655 4.49 $ 0.50 521 $ 0.50 $0.51 - $1.00 393 5.36 $ 0.78 196 $ 0.78 $1.01 - $25.00 2 2.32 $ 15.94 2 $ 15.94 $25.01 – $625.00 17 1.77 $ 28.12 17 $ 28.12 Total 1,067 4.76 $ 1.07 736 $ 1.25 A summary of the status of the Company's non-vested shares as of March 31, 2020 is as follows: Non-vested Shares Shares Weighted Average Non-vested at January 1, 2020 417 $ 0.65 Vested (86 ) $ 0.67 Non-vested at March 31, 2020 331 $ 0.67 As of March 31, 2020, there was $75 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 1.03 years. Warrants The Company did not issue any warrants during the three months ended March 31, 2020. On February 6, 2019, the Company issued warrants to purchase 985,000 shares of common stock to 4 consultants and an employee in connection with the accrued compensation owed by the Company to the employee and consultants. The warrants are exercisable for three years with an exercise price of $0.50 per share. The warrants may not be exercised for cash or on a cashless basis, and may solely be exercised using the holder's outstanding accrued compensation on the date of exercise. A summary of the warrant activity to purchase shares of Common Stock for the three months ended March 31 is as follows: 2020 2019 Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Outstanding at beginning of period 2,536 $ 1.52 1,828 $ 2.08 Issued - $ 985 $ 0.50 Outstanding at end of period 2,536 $ 1.52 2,813 $ 1.53 Exercisable at end of period 2,536 $ 1.52 2,813 $ 1.53 A summary of the status of the warrants outstanding and exercisable to purchase shares of Common Stock as of March 31, 2020 is as follows: Number of Shares Weighted Average Remaining Life Weighted Average Exercise Price per share 1,551 1.15 $ 2.18 985 1.88 $ 0.50 2,536 1.43 $ 1.52

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent event	6. Subsequent event On May 6, 2020, the Company received loan proceeds in the amount of approximately $123,077 under the Paycheck Protection Program ("PPP"). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act ("CARES Act"), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. The Company intends to use the proceeds for purposes consistent with the PPP. While the Company currently believes that its use of the loan proceeds, for the most part, will meet the conditions for forgiveness of the loan, we cannot assure you that we will not take actions that could cause the Company to be ineligible for forgiveness of the loan, in whole or in part.

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Nature of Business	Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign's solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign's platform can be deployed both on premise and as a cloud-based ("SaaS") service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company's products include SignatureOne™ Ceremony™ Server, the iSign™ suite of products and services, including iSign™ Enterprise and iSign™ Console™, and Sign-it™ programs. In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread to a number of other countries, including the U.S. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, several states in the U.S., including California, where the Company is headquartered, have declared a state of emergency. The COVID-19 outbreak is disrupting supply chains and affecting production and sales across a wide range of industries. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our customers, employees and vendors all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact our financial condition or results of operations is uncertain.
Basis of Presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2019. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
Going Concern	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2020 the Company's accumulated deficit was $135,014. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2020, the Company's cash balance was $88. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accounting Changes and Recent Accounting Pronouncements	Accounting Changes and Recent Accounting Pronouncements Accounting Standards Update No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interaction between Topic 321, Topic 323 and Topic 815. The amended guidance in this update was issued to clarify the interaction of the accounting for equity securities under Topic 321, Investments—Equity Securities; investments accounted for under the equity method of accounting in Topic 323, Investments—Equity Method and Joint Ventures; and the accounting for certain forward contracts and purchased options accounted for under Topic 815, Derivatives and Hedging. The amendments are effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company will evaluate ASU 2020-01. The Company believes the adoption of ASU 2020-01 will have no impact on the Company's financial statements. Accounting Standards Update No. 2020-03, Codification Improvements to Financial Instruments. The Board decided to issue a separate update to improve various financial instruments Topics in the Codification to increase stakeholder awareness of the amendments and to clarify and improve the understandability of the guidance of Topics. The amendments are effective immediately. The Company believes the adoption of ASU 2020-03 will have no impact on the Company's financial statements.

Concentrations (Tables)

Concentrations (Tables)	3 Months Ended
	Mar. 31, 2020
Risks and Uncertainties [Abstract]
Schedule of accounts receivable and revenue concentrations	Accounts Receivable Total Revenue 2020 2019 2020 2019 Customer #1 - - 12 % 12 % Customer #2 85 % 83 % 18 % 17 % Customer #3 - - 18 % 18 % Customer #4 - - 26 % 20 % Customer #5 13 % - - - Total concentration 98 % 83 % 74 % 67 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Net Loss Per Share [Abstract]
Schedule of options and warrants would be anti-dilutive	For the Three Months Ended March 31, 2020 March 31, 2019 Stock options 1,067 1,077 Warrants 2,536 2,813

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of fair value calculations for the stock options granted	Three Months Ended Risk free interest rate 2.30 % Expected life (years) 6.1 Expected volatility 191.65 % Expected dividend yield None
Schedule of allocation of stock-based compensation expense	2020 2019 Research and development $ 3 $ 10 Sales and marketing - ─ General and administrative 16 40 Director 3 9 Total stock-based compensation $ 22 $ 59
Schedule of option activity under the Company's plans	2020 2019 Options Shares Weighted Average Exercise Price per share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price per share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1 1,077 $ 1.59 - $ - 1,037 $ 1.65 - - Granted - $ - - - 40 $ 0.50 - - Canceled (10 ) $ 56.10 Outstanding at March 31 1,067 $ 1.07 4.76 $ - 1,077 $ 1.61 5.72 - Vested and expected to vest at March 31 1,062 $ 1.59 4.92 $ - 1,077 $ 1.61 5.72 $ - Exercisable at March 31 736 $ 1.25 4.60 $ - 402 $ 3.24 5.28 $ -
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.01 - $0.50 655 4.49 $ 0.50 521 $ 0.50 $0.51 - $1.00 393 5.36 $ 0.78 196 $ 0.78 $1.01 - $25.00 2 2.32 $ 15.94 2 $ 15.94 $25.01 – $625.00 17 1.77 $ 28.12 17 $ 28.12 Total 1,067 4.76 $ 1.07 736 $ 1.25
Schedule of the company's non-vested shares	Non-vested Shares Shares Weighted Average Non-vested at January 1, 2020 417 $ 0.65 Vested (86 ) $ 0.67 Non-vested at March 31, 2020 331 $ 0.67
Schedule of warrant activity	2020 2019 Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Outstanding at beginning of period 2,536 $ 1.52 1,828 $ 2.08 Issued - $ 985 $ 0.50 Outstanding at end of period 2,536 $ 1.52 2,813 $ 1.53 Exercisable at end of period 2,536 $ 1.52 2,813 $ 1.53
Schedule of warrants outstanding and exercisable	Number of Shares Weighted Average Remaining Life Weighted Average Exercise Price per share 1,551 1.15 $ 2.18 985 1.88 $ 0.50 2,536 1.43 $ 1.52

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Nature of Business and Summary of Significant Accounting Policies (Textual)
Accumulated deficit	$ (135,014)	$ (134,675)
Cash balance	$ 88	$ 25	$ 280	$ 335

Concentrations (Details)

Concentrations (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accounts Receivable [Member]
Concentration Risk [Line Items]
Total concentration	98.00%	83.00%
Accounts Receivable [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration	85.00%	83.00%
Accounts Receivable [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration	13.00%
Total Revenue [Member]
Concentration Risk [Line Items]
Total concentration	74.00%	67.00%
Total Revenue [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration	12.00%	12.00%
Total Revenue [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration	18.00%	17.00%
Total Revenue [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration	18.00%	18.00%
Total Revenue [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration	26.00%	20.00%
Total Revenue [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net Loss Per Share [Abstract]
Stock options	1,067	1,077
Warrants	2,536	2,813

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2020	Jan. 31, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 25, 2020
Debt (Textual)
Aggregating amount of debt	$ 75	$ 75	$ 75
Debt instrument, description			Upon collection of an invoice, the Company agreed to repay the advance to the lenders on a pro rata basis together with a 5% advance fee. On March 25, 2020 the affiliates converted their advances into unsecured notes. The Company paid the advance fees of $4 in cash, and recorded them as interest expense in the quarter ended March 31, 2020.
Amortization of debt discount				$ 10
Unsecured convertible notes					$ 150
Secured Convertible Promissory Notes [Member]
Debt (Textual)
Conversion rate per shares	$ 0.50		$ 0.50
Aggregate proceeds of new financing			$ 1,000
Secured notes bear interest rate			10.00%
Secured notes due date			Dec. 31, 2020
Amount exchanged for advances			$ 75
Accrued interest expense			69	61
Accrued interest to related parties			24	13
Accrued Interest to other investors			36	40
Amortization of debt discount			0	10
Unsecured convertible notes	$ 60		$ 60	$ 53

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) (Details)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Risk free interest rate	2.30%
Expected life (years)	6 years 1 month 6 days
Expected volatility	191.65%
Expected dividend yield

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 22	$ 59
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	3	10
Sales and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	16	40
Director [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 3	$ 9

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details 2) - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Shares
Exercisable at March 31			736
Option [Member]
Shares
Outstanding at January 1	1,077	1,037
Granted		40
Canceled	(10)
Outstanding at March 31	1,067	1,077
Vested and expected to vest at March 31	1,062	1,077
Exercisable at March 31			736	402
Weighted Average Exercise Price Per share
Outstanding at January 1	$ 1.59	$ 1.65
Granted		0.50
Canceled	56.10
Outstanding at March 31	1.25	3.24
Vested and expected to vest at March 31	1.59	1.61
Exercisable at March 31	$ 1.59	$ 3.24	$ 1.25	$ 3.24
Weighted Average Remaining Contractual Life Term (in years)
Outstanding at March 31	4 years 9 months 3 days	5 years 8 months 19 days
Vested and expected to vest at March 31	4 years 11 months 1 day	5 years 8 months 19 days
Exercisable at March 31	4 years 7 months 6 days	5 years 3 months 11 days
Aggregate Intrinsic Value
Outstanding at January 1
Granted
Canceled
Outstanding at March 31
Vested and expected to vest at March 31
Exercisable at March 31

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Details 3) shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,067
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	4 years 9 months 3 days
Options Outstanding, Weighted Average Exercise Price	$ 1.07
Options Exercisable, Number Outstanding | shares	736
Options Exercisable, Weighted Average Exercise Price	$ 1.25
$0.01 - $0.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.01
Range of Exercise Prices, Upper Range Limit	$ 0.50
Options Outstanding, Number Outstanding | shares	655
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	4 years 5 months 27 days
Options Outstanding, Weighted Average Exercise Price	$ 0.50
Options Exercisable, Number Outstanding | shares	521
Options Exercisable, Weighted Average Exercise Price	$ 0.50
$0.51 - $1.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.51
Range of Exercise Prices, Upper Range Limit	$ 1
Options Outstanding, Number Outstanding | shares	393
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	5 years 4 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 0.78
Options Exercisable, Number Outstanding | shares	196
Options Exercisable, Weighted Average Exercise Price	$ 0.78
$1.01 - $25.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	1.01
Range of Exercise Prices, Upper Range Limit	$ 25
Options Outstanding, Number Outstanding | shares	2
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	2 years 3 months 26 days
Options Outstanding, Weighted Average Exercise Price	$ 15.94
Options Exercisable, Number Outstanding | shares	2
Options Exercisable, Weighted Average Exercise Price	$ 15.94
$25.01 - $625.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	25.01
Range of Exercise Prices, Upper Range Limit	$ 625
Options Outstanding, Number Outstanding | shares	17
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	1 year 9 months 7 days
Options Outstanding, Weighted Average Exercise Price	$ 28.12
Options Exercisable, Number Outstanding | shares	17
Options Exercisable, Weighted Average Exercise Price	$ 28.12

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Details 4) shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Shares
Non-vested, Beginning balance | shares	417
Vested | shares	(86)
Non-vested, Ending balance | shares	331
Weighted Average Grant-Date Fair Value
Non-vested, Beginning balance | $ / shares	$ 0.65
Vested | $ / shares	0.67
Non-vested, Ending balance | $ / shares	$ 0.67

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) (Details 5) - Warrant [Member] - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Outstanding at beginning of period	2,536	1,828
Shares, Issued		985
Shares, Outstanding at end of period	2,536	2,813
Shares, Exercisable at end of period	2,536	2,813
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$ 1.52	$ 2.08
Weighted Average Exercise Price Per Share, Issued		0.50
Weighted Average Exercise Price Per Share, Outstanding at end of period	1.52	1.53
Weighted Average Exercise Price Per Share, Exercisable at end of period	$ 1.52	$ 1.53

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) (Details 6) shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Warrants | shares	2,536
Weighted Average Remaining Life (years)	1 year 5 months 5 days
Weighted Average Exercise Price per share | $ / shares	$ 1.52
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	1,551
Weighted Average Remaining Life (years)	1 year 1 month 24 days
Weighted Average Exercise Price per share | $ / shares	$ 2.18
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	985
Weighted Average Remaining Life (years)	1 year 10 months 17 days
Weighted Average Exercise Price per share | $ / shares	$ 0.50

Stockholders' Equity (Deficit_7

Stockholders' Equity (Deficit) (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 06, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Stockholders' Equity (Deficit) (Textual)
Total unrecognized compensation cost		$ 75
Weighted average period		1 year 11 days
Common stock value		$ 58		$ 58
Warrants [Member]
Stockholders' Equity (Deficit) (Textual)
Granted, weighted average exercise price per share	$ 0.50
Common stock warrants purchased	985
Stock options [Member]
Stockholders' Equity (Deficit) (Textual)
Granted, weighted average exercise price per share			$ 0.50
Common stock value			$ 40